These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 1569169)

  • 1. Assessment of depot leuprolide acetate dose-adequacy for central precocious puberty.
    Cook JS; Doty KL; Conn PM; Hansen JR
    J Clin Endocrinol Metab; 1992 May; 74(5):1206-9. PubMed ID: 1569169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls.
    Brito VN; Latronico AC; Arnhold IJ; Mendonca BB
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4338-42. PubMed ID: 15356030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between luteinizing hormone and estradiol secretion in female precocious puberty: evaluation by sensitive gonadotropin assays and the leuprolide stimulation test.
    Garibaldi LR; Aceto T; Weber C; Pang S
    J Clin Endocrinol Metab; 1993 Apr; 76(4):851-6. PubMed ID: 8473395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of gonadotrophin suppression in girls treated with GnRH analogue for central precocious puberty; validity of single luteinizing hormone measurement after leuprolide acetate injection.
    Demirbilek H; Alikasifoglu A; Gonc NE; Ozon A; Kandemir N
    Clin Endocrinol (Oxf); 2012 Jan; 76(1):126-30. PubMed ID: 21790701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty.
    Lee PA; Klein K; Mauras N; Neely EK; Bloch CA; Larsen L; Mattia-Goldberg C; Chwalisz K
    J Clin Endocrinol Metab; 2012 May; 97(5):1572-80. PubMed ID: 22344198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of gonadotropin secretion by a long-acting gonadotropin-releasing hormone analog (leuprolide acetate, Lupron Depot) in children with precocious puberty.
    Kappy M; Stuart T; Perelman A; Clemons R
    J Clin Endocrinol Metab; 1989 Nov; 69(5):1087-9. PubMed ID: 2507570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring treatment of central precocious puberty using basal luteinizing hormone levels and practical considerations for dosing with a 3-month leuprolide acetate formulation.
    Lee PA; Luce M; Bacher P
    J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1249-1257. PubMed ID: 27740929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty.
    Lee PA; Klein K; Mauras N; Lev-Vaisler T; Bacher P
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3153-9. PubMed ID: 24926950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-year results of treatment with depot leuprolide acetate for central precocious puberty.
    Neely EK; Hintz RL; Parker B; Bachrach LK; Cohen P; Olney R; Wilson DM
    J Pediatr; 1992 Oct; 121(4):634-40. PubMed ID: 1403402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of three doses of leuprolide acetate in the treatment of central precocious puberty: preliminary results.
    Mericq V; Lammoglia JJ; Unanue N; Villaroel C; Hernández MI; Avila A; Iñiguez G; Klein KO
    Clin Endocrinol (Oxf); 2009 Nov; 71(5):686-90. PubMed ID: 19302581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty.
    Badaru A; Wilson DM; Bachrach LK; Fechner P; Gandrud LM; Durham E; Wintergerst K; Chi C; Klein KO; Neely EK
    J Clin Endocrinol Metab; 2006 May; 91(5):1862-7. PubMed ID: 16449344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depot leuprolide acetate dosage for sexual precocity.
    Parker KL; Baens-Bailon RG; Lee PA
    J Clin Endocrinol Metab; 1991 Jul; 73(1):50-2. PubMed ID: 1904452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in body mass index during gonadotropin-releasing hormone agonist treatment for central precocious puberty and early puberty.
    Lee HS; Yoon JS; Roh JK; Hwang JS
    Endocrine; 2016 Nov; 54(2):497-503. PubMed ID: 27444748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of central precocious puberty: comparison of urinary gonadotropin excretion and gonadotropin-releasing hormone (GnRH) stimulation tests in monitoring GnRH analog therapy.
    Witchel SF; Baens-Bailon RG; Lee PA
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1353-6. PubMed ID: 8636332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteinizing hormone (LH) and estradiol suppression and growth in girls with central precocious puberty: is more suppression better? Are pre-injection LH levels useful in monitoring treatment?
    Kunz GJ; Sherman TI; Klein KO
    J Pediatr Endocrinol Metab; 2007 Nov; 20(11):1189-98. PubMed ID: 18183790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty.
    Klein KO; Freire A; Gryngarten MG; Kletter GB; Benson M; Miller BS; Dajani TS; Eugster EA; Mauras N
    J Clin Endocrinol Metab; 2020 Oct; 105(10):e3660-71. PubMed ID: 32738042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty.
    Fuld K; Chi C; Neely EK
    J Pediatr; 2011 Dec; 159(6):982-7.e1. PubMed ID: 21798557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.
    Boepple PA; Mansfield MJ; Wierman ME; Rudlin CR; Bode HH; Crigler JF; Crawford JD; Crowley WF
    Endocr Rev; 1986 Feb; 7(1):24-33. PubMed ID: 2937629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated Pre-injection Basal Luteinizing Hormone Concentrations are Common in Girls Treated for Central Precocious Puberty.
    Schubert S; Hvelplund AH; Handberg A; Hagstroem S; Leunbach TL
    J Clin Res Pediatr Endocrinol; 2021 Jun; 13(2):204-211. PubMed ID: 33374097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with Depot Leuprolide Acetate in Girls with Idiopathic Precocious Puberty: What Parameter should be Used in Deciding on the Initial Dose?
    Vurallı D; Alikaşifoğlu A; İyigün İ; Canoruç D; Ozon A; Gönç N; Kandemir N
    J Clin Res Pediatr Endocrinol; 2020 Mar; 12(1):37-44. PubMed ID: 31347350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.